HK1201204A1 - Methods for treating a stroke-related sensorimotor impairment using aminopyridines - Google Patents

Methods for treating a stroke-related sensorimotor impairment using aminopyridines Download PDF

Info

Publication number
HK1201204A1
HK1201204A1 HK15101829.8A HK15101829A HK1201204A1 HK 1201204 A1 HK1201204 A1 HK 1201204A1 HK 15101829 A HK15101829 A HK 15101829A HK 1201204 A1 HK1201204 A1 HK 1201204A1
Authority
HK
Hong Kong
Prior art keywords
stroke
aminopyridines
methods
treating
sensorimotor impairment
Prior art date
Application number
HK15101829.8A
Other languages
English (en)
Chinese (zh)
Inventor
R. Blight Andrew
O. Caggiano Anthony
J. Parry Tom
F. Iaci Jennifer
Original Assignee
Acorda Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics, Inc. filed Critical Acorda Therapeutics, Inc.
Publication of HK1201204A1 publication Critical patent/HK1201204A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
HK15101829.8A 2011-10-04 2012-10-04 Methods for treating a stroke-related sensorimotor impairment using aminopyridines HK1201204A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161543150P 2011-10-04 2011-10-04
US61/543,150 2011-10-04
US201261591833P 2012-01-27 2012-01-27
US61/591,833 2012-01-27
US201261648695P 2012-05-18 2012-05-18
US61/648,695 2012-05-18
PCT/US2012/058607 WO2013052575A1 (en) 2011-10-04 2012-10-04 Methods for treating a stroke-related sensorimotor impairment using aminopyridines

Publications (1)

Publication Number Publication Date
HK1201204A1 true HK1201204A1 (en) 2015-08-28

Family

ID=47143280

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101829.8A HK1201204A1 (en) 2011-10-04 2012-10-04 Methods for treating a stroke-related sensorimotor impairment using aminopyridines

Country Status (22)

Country Link
US (2) US20130085167A1 (enExample)
EP (1) EP2766017B1 (enExample)
JP (1) JP6134722B2 (enExample)
KR (1) KR20140084120A (enExample)
CN (2) CN104220072B (enExample)
AR (1) AR088764A1 (enExample)
AU (2) AU2012318719B2 (enExample)
BR (1) BR112014008082A8 (enExample)
CA (1) CA2850635A1 (enExample)
CL (1) CL2014000799A1 (enExample)
CO (1) CO7061067A2 (enExample)
CR (1) CR20140153A (enExample)
EA (1) EA029558B1 (enExample)
HK (1) HK1201204A1 (enExample)
IL (1) IL231809B (enExample)
MX (1) MX354667B (enExample)
PH (1) PH12014500739B1 (enExample)
SG (2) SG11201401248YA (enExample)
TW (1) TWI592156B (enExample)
UA (1) UA114486C2 (enExample)
WO (1) WO2013052575A1 (enExample)
ZA (1) ZA201402432B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2909527A1 (en) * 2013-04-15 2014-10-23 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
DE102017115701B4 (de) * 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS
CN109172573B (zh) * 2018-09-12 2021-01-26 黑龙江中桂制药有限公司 一种口服抗血栓药物及其用途
CN115018836A (zh) * 2022-08-08 2022-09-06 四川大学 一种癫痫病灶自动分割与预测方法、系统及设备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0696575B2 (ja) * 1987-09-17 1994-11-30 三菱化成株式会社 4−アミノピリジン誘導体及びその酸付加塩
WO1989009600A1 (en) 1988-04-08 1989-10-19 Massachusetts Institute Of Technology Method and composition for treating neurological disorders
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
CA2085785C (en) * 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
US5952357A (en) 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
EP1152760B1 (en) * 1999-02-09 2007-03-28 UAB Research Foundation Use of 4-amino pyridine for treatment of peripheral neuropathies
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
CA2403555A1 (en) * 2000-03-28 2001-10-04 Queen's University At Kingston Methods for effecting neuroprotection
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP2667869A1 (en) * 2011-01-28 2013-12-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy

Also Published As

Publication number Publication date
JP6134722B2 (ja) 2017-05-24
AU2012318719A1 (en) 2014-04-17
SG11201401248YA (en) 2014-05-29
US20130085167A1 (en) 2013-04-04
EA029558B1 (ru) 2018-04-30
CR20140153A (es) 2014-07-04
KR20140084120A (ko) 2014-07-04
IL231809A0 (en) 2014-05-28
CN104220072B (zh) 2018-04-17
NZ623255A (en) 2016-08-26
UA114486C2 (uk) 2017-06-26
SG10201600410SA (en) 2016-02-26
PH12014500739A1 (en) 2014-05-26
IL231809B (en) 2019-06-30
MX354667B (es) 2018-03-15
TW201321000A (zh) 2013-06-01
ZA201402432B (en) 2020-08-26
AU2012318719B2 (en) 2017-10-19
TWI592156B (zh) 2017-07-21
PH12014500739B1 (en) 2019-05-10
US20160067232A1 (en) 2016-03-10
WO2013052575A1 (en) 2013-04-11
BR112014008082A8 (pt) 2018-01-16
EP2766017A1 (en) 2014-08-20
CA2850635A1 (en) 2013-04-11
AU2018200114A1 (en) 2018-01-25
EP2766017B1 (en) 2020-07-01
HK1204965A1 (en) 2015-12-11
CL2014000799A1 (es) 2014-11-03
CO7061067A2 (es) 2014-09-19
BR112014008082A2 (pt) 2017-07-18
CN104220072A (zh) 2014-12-17
JP2014531470A (ja) 2014-11-27
EA201490562A1 (ru) 2014-08-29
MX2014003997A (es) 2014-07-22
AR088764A1 (es) 2014-07-02
CN108451953A (zh) 2018-08-28

Similar Documents

Publication Publication Date Title
PH12013500577A1 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
WO2013052907A8 (en) Methods and processes for non-invasive assessment of genetic variations
EP2511273B8 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses
IL229257A0 (en) Compositions and methods for treating retinal diseases
IL231386A (en) Pyrazolequinoline derivatives, their preparation and medical use
EP2437602A4 (en) OPHTHALMIC FORMULATIONS, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THEIR USE
TN2012000414A1 (en) Forms of rifaximin and uses thereof
AP2012006339A0 (en) Methods of administering pirfenidone therapy.
TN2011000403A1 (en) Compositions and methods for extended therapy wiht aminopyridines
GB201106943D0 (en) Improvements in or relating to password generation, recall and protection
PL2694538T3 (pl) Sposoby terapeutyczne i profilaktyczne, zastosowania i kompozycje zawierające aneksynę a5
PH12016500136A1 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
IL233238A (en) Sulphonylaminopyrrolidinone derivatives, their preparation and therapeutic use
EP2663326A1 (en) Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
MY166463A (en) Positive allosteric modulators of nicotinic acetylcholine receptor
HK1216095A1 (zh) 烟碱乙酰胆碱受体的新的正向别构调节剂
PH12014500739B1 (en) Methods for treating a stroke-related sensorimotor impairment using aminopyridines
WO2011029082A8 (en) Durable treatment with 4-aminopyridine in patients with demyelination
WO2012006585A3 (en) Use of interleukin-15 to treat cardiovascular diseases
WO2013074816A3 (en) Novel inhibitors of nox1
WO2013057554A3 (en) Therapeutic combinations of netupitant and palonosetron
WO2012119045A3 (en) Compositions and uses thereof to ameliorate pain
HK1221666A1 (zh) 氨基吡啶用於治疗与某些中风类型相关的视觉障碍的方法
HK1188168A (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
UA104307C2 (ru) Способ продолжительной терапии с применением 4-аминопиридина